CHRS — Coherus Oncology, Inc.

Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Sales: LOQTORZI net sales increased by 61% year-over-year, totaling $11.8 million for Q1 2026, down slightly from $12.4 million in Q4 2025, attributed to typical seasonal trends and severe weather impacts.
• Revenue Guidance: The company projects reaching $15 million per quarter in 2026, $30 million to $35 million per quarter in 2027, and a peak of $44 million per quarter by 2028, translating to an annualized $175 million.
• Operating Expenses: R&D expenses decreased to $21.5 million from $24.4 million year-over-year, while SG&A expenses fell to $23.1 million from $26 million, reflecting cost management and the exit from the biosimilar business.
• Cash Position: Total cash, cash equivalents, and investments at the end of the quarter were $167 million, down from $172.1 million at year-end, but sufficient to fund ongoing studies through 2026 and 2027.

2. Strategic Updates and Business Highlights

• Product Pipeline: The company is focusing on LOQTORZI, a PD-1 inhibitor, and advancing its pipeline assets, including casdozokitug and tagmokitug, across various cancer indications.
• Clinical Development: Successful accrual in the CATALYST-202 study for casdozokitug in hepatocellular carcinoma, with initial data expected mid-year. Tagmokitug is being explored in multiple cohorts for head and neck and gastrointestinal cancers.
• Commercial Strategy: Increased visibility into treatment patterns through claims data, targeting education on NCCN guidelines to reduce off-label PD-1 use, and expanding the inside sales team to enhance community outreach.

3. Forward Guidance and Outlook

• The company maintains a positive outlook for revenue growth, expecting a return to growth in LOQTORZI sales in subsequent quarters after Q1's seasonal decline.
• Continued focus on driving demand through enhanced commercial strategies and targeted investments, with a goal of achieving significant market penetration in the oncology space.

4. Bad News, Challenges, or Points of Concern

• Seasonal Impact: Severe winter weather affected patient treatment cycles, leading to a decline in sales despite strong new patient starts.
• Competitive Landscape: The evolving CCR8 antibody market poses risks, as some competitors are halting programs due to safety and efficacy concerns, while others advance, creating a mixed competitive environment.
• Clinical Development Risks: The success of ongoing trials is crucial, and any setbacks could impact future revenue projections and market positioning.

5. Notable Q&A Insights

• Treatment Duration: The average duration of LOQTORZI treatment is increasing, particularly among first-line patients, with 75%-80% of new patients coming from the metastatic setting.
• Data Expectations: Investors should look for overall response rates and clinical benefit from upcoming tagmokitug data readouts, with a focus on durability and potential regulatory pathways.
• Market Dynamics: There is recognition of the need to address the competitive landscape, particularly with emerging therapies in head and neck cancer, and the importance of differentiating LOQTORZI from off-label PD-1 use.

Overall, Coherus Oncology is navigating a complex landscape with a strong pipeline and strategic focus on growth, but faces challenges from market dynamics and operational execution that will require careful management.